Metrics as of 10/15/2026, 10:17 PM (Berlin time), refresh in progress.
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company within the Healthcare sector and functions as a subsidiary of the ZEISS Group. Headquartered in Jena, Germany, the company was founded in 1846. Its business activities span across Germany, the rest of Europe, North America, and Asia. The company is…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
1D
+0.9%
1W
+1.9%
1M
+9.0%
6M
+18.6%
YTD
-17.4%
1Y
-29.6%
2Y
-46.1%
5Y
-80.2%
10Y
-4.0%
Next earnings date
No date known
Volatility around earnings
~70% stronger price swings than usual
Visible after free registration
Visible after free registration
Visible after free registration
Visible after free registration
Visible after free registration
Visible after free registration
Visible after free registration
Visible after free registration
Visible after free registration
Visible after free registration
Register for free
Unlock all 11 scores
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
P/E
19.8
P/B
1.35
EV/EBITDA
8.75
RETURN ON EQUITY
2.6%
NET MARGIN
9.8%
DEBT/EQUITY
0
DIVIDEND YIELD
1.7%
AS OF
30/06/2026
FREE FLOAT
39.1%
FLOAT SHARES
34,188,008
AVG. DAILY VOLUME (30D)
157,126
Carl Zeiss Meditec AG is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in Germany.
The CEO is Andreas Pecher, the company employs around 5,784 people.
The IPO was on 22/03/2000; the stock trades on XETRA under the ticker AFX.DE.
Around past earnings, price swings were roughly 70% stronger than usual.
Yes. The last dividend was €0.55 per share, ex-date 27/03/2026, paid on 31/03/2026.
The dividend yield is 1.7% (as of 30/06/2026).
Comparable stocks include Sartorius, Anbio Biotechnology, Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum and Baxter International.
Clicking "Analyze stock" lets five strategies assess Carl Zeiss Meditec against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.